Dr. Richard Allen is the Endocrinology Reviewer at GLPOneMedical. He reviews diabetes, thyroid, and metabolic-disease content across the publication and is the lead reviewer for the STEP, SURMOUNT, SURPASS, and SUSTAIN trial program summaries.
Background
Dr. Allen is a board-certified physician in internal medicine and endocrinology. His clinical interest has focused on the pharmacotherapy of type 2 diabetes and the management of obesity in patients with comorbid metabolic disease.
Role at GLPOneMedical
As Endocrinology Reviewer, Dr. Allen:
- Reviews all pages related to diabetes, prediabetes, thyroid disease, and the endocrine effects of GLP-1 receptor agonist therapy.
- Is the lead reviewer for trial-summary pages covering the STEP program (semaglutide weight), SURMOUNT program (tirzepatide weight), SURPASS program (tirzepatide T2D), and SUSTAIN program (semaglutide T2D).
- Reviews the indication-specific pages on type 2 diabetes, prediabetes, and metabolic syndrome.
- Reviews contraindication and drug-interaction content related to endocrine indications.
Areas of expertise
- Endocrinology — diabetes, thyroid, pituitary, adrenal disease.
- Type 2 diabetes pharmacotherapy — GLP-1 RAs, SGLT2 inhibitors, insulin, sulfonylureas, dual-agonists.
- Obesity in T2D — combined glycemic and weight management.
- The MTC boxed warning — what the rodent data show, what human evidence has accumulated, who is genuinely contraindicated.
Recent reviews signed off
- STEP trial program summary
- SURMOUNT trial program summary
- GLP-1 and type 2 diabetes
- Contraindications (MTC / MEN-2 sections)
Conflicts of interest
None disclosed beyond the standard editorial-retainer arrangement with Ranika Partners LLC. No advisory or compensation relationships with any provider reviewed on this site. Full conflicts disclosure: /conflicts-of-interest.html.
Contact
glponemedical@gmail.com (subject line: "Medical advisory board / Dr. Allen").